MXPA97003232A - New antagonists of the muscarin receiver - Google Patents

Abstract

The present invention relates to: A compound of formula wherein: X is NR4R5, Y is N or CH; Z is pyridyl or phenyl optionally substituted with one to three substituents independently selected from C1-C6 alkyl, halogen, hydroxy, alkoxy of C 1 -C 6, amino, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, and trifluoromethoxy; R 2 is phenyl optionally substituted with one to three substituents independently selected from C 1 -C 6 alkyl, halogen, hydroxy, C 1 -C 6 alkoxy , amino, C1-C6 alkylamino, C1-C6 dialkylamino, -CF3, -CN, -COR6, NHCOR6 and trifluoromethoxy; R3 is phenyl optionally substituted with one to three substituents independently selected from C1-C6 alkyl, halogen, hydroxy , C 1 -C 6 alkoxy, amino, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, and trifluoromethoxy; R 4 and R 5 are independently C 1 -C 10 alkyl or R 4 and R 5 taken together with nitrogen atom to which they are attached form a ring saturated heterocyclic of five to nine members, wherein the ring atoms may be optionally replaced with a heteroatom selected from nitrogen, oxygen and sulfur, wherein said saturated five to nine membered heterocyclic ring may be optionally substituted with one to three substituents independently selected from -OR, alkyl, C1-C4, oxo and a ketal of the formula -O- (CH2) mO-; with the proviso that said substituted heterocycles can not be substituted together with a heteroatom by hydroxy or a ketal; m is an integer of one to three, R6 is hydrogen or C1-C6 alkyl, and pharmaceutically acceptable salts thereof

Description

ANTIGONISTS OF THE MUSCARINTH RECEPTOR ANTECEDENTS OF THE INVENTION This invention relates to a new class of partial or total muscarinic receptor agonists, to intermediates for their preparation and to pharmaceutical compositions and methods of use for the treatment or prevention of diseases, treatment or prevention of diseases of which it is mediated by the agonist action on the muscarinic receptor. Some described compounds exhibit uscarinic antagonist activity or agonist / antagonist mixed activity and are therefore useful for the treatment or prevention of diseases or syndrome characterized by excessive cholinergic activity. The uscarinic receptors are pre- and post-synaptic receptors in the cholinergic neurotransmitter system. The alteration of the cholinergic neurotransmitter system has been related < Jo with central nervous system dysfunction (CNS) related to age. Those skilled in the art believe that muscarinic receptor agonists are useful in the treatment or prevention of age-related CNS dysfunction, as cognitive decline and Alzheimer's disease are consequences of the alteration of the seventh. cholinergic neurotransrnisor. The specific evidence of the role of the cholinergic neurotransmitter system in "Jel SNC-related age dysfunction" has been published by Baruts, R.T. et al., in The Cholinergic Hypothesis of Geriatric Memory Disfunction. Science, 217, 408-417 (1982). The authors argue that an alteration in the central cholinergic system may be responsible for the age-related deterioration of the CNS. (See also, Perry, E.K., The Cholinergic Hypothesis - Ten Years On, Br. Med. Bull., 42, 63-69 (1986)). More evidence supporting the cholinergic hypothesis has been presented by Si s, et al., Presynaptic Cholinergic Disfunction in Patients with Disease, 3. Neurochern., 40, 503-509 (1983). These authors have shown that the cholinergic neurotransmitter system is implicated in CNS disorders related to age, showing that the activity of cholinergic markers such as colin acetyltransferase is markedly reduced in the brains of patients with Alzheirner's disease (AD). compared to controls matched by age. It has also been seen that the cholinergic neurons that originate in the basal nucleus of Meynert and that project in the hippocampus and in the cortex, present a great degeneration in Alzheimer's disease. See Vogel et al. Cell Loss and Shrinkage in the Nucleus Basalis Meynert Complex in Alzheimer's Disease. Neurobiol. Aging, 11, 3-13 (1990); and Uhitehouse et al., Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain, Science, 215, 1237-1239 (1982).

Likewise, it has been shown that antagonists such as scopolarnin can cause cognitive deterioration in normal subjects in a similar way - as happens in those of normal age. See Sitara, et al., Human Serial Learning: Enhancement with Arecoline and Choline and Irnpairment? Ith Scopola ine. Science, 201, 274-276 (1978); and Drachman D.A Memory and Cognitive Function in Man: Does the Cholinergic System Have a Specific Role? Neurology, 27, 783-790 (1977). Based on all external investigations, it is commonly believed that the enhancement of central cholinergic action would be a useful treatment for disorders that present with a cognitive decline. One strategy to reinforce cholinergic neurotransmission has been to mimic the action of acetylcholine on the uscarinic receptors with the appropriate agonists. There are three pharmacologically defined receptors (M Ma) and five human receptors (m -rns) have recently been cloned (Bonner, et al., Identification of a Family of M? Scarinic Acetylcholine Receptor Genes, Science, 237, 527-532 (1987 ); and Bonner The Molecular Basis of Muscarinic Receptor Diversity, T.I.N.S., 12, 148-151 (1989). Due to the lack of highly selective ligands for each of the subtypes, it has not been possible to unequivocally establish the biological role of individual receptors, however, it is believed that central rn * receptors mediate cognition and subtypes rns -ms are responsible for the side effects (salivation, lacrimation, diarrhea). The "Inrunopresipitation" studies have shown that there is a preponderance of the m receptor in the cortex and in the hippocampus, areas of the brain involved in memory and learning. Ideally, a selective m agonist would be a desirable agent for the treatment of cognitive decline related to neurodegenerative disorders. In addition to age-related cognitive decline, nuscarinic agents are also known to be effective in the treatment of seasonal and delayed dyskinesia. It is known that muscarinic agents influence schizophrenia and other psychotic disorders and atypical antipsychotic clozapine possesses selective Jel m4 agonist activity, which is important for its clinical profile (Zorn et al., Clozapine is a Potent and Selective Muscarinic M4). Receptor Agonist, Eu 3. Pharrnacol., 269, Rl R2 (1994) Clozapine is also used to treat tardive dyskinesia, which frequently appears after treatment with typical antipsychotics, It is also known that rnuscarinic agonists produce strong analgesia, comparable with that produced by opioid analgesics (P. Hartvin, et al., Cholinergic Mechanisms in pain and analgesia, Trends Pharmacol. Sci., 9, 75-79, (1989)).

It is also believed that the uscarinic antagonists are effective agents in the treatment of diseases or syndromes characterized by overactivation of muscarinic receptors. Collagen regulation of sleep, especially in the REM phase, indicates that muscarinic agents would be useful in the treatment of sleep disorders, such as insomnia and drowsiness (D. Reimann et al., Cholinergic Neurotrans ionsion, REM Sleep and Depression , 3. Psychosom, Res., 38, 15-25, (.1994)). The uscarinic systems also modulate psychiatric depression (K. Davis et al., Induction of Depression whith Oxotre orine in Patients with Alzheirner's Diesease, Arn 3. Psychiatry, 144, 468-471, (1987)), including the disorder seasonal cash (SC Disalver et al., Brright Artificial Light Subsubsitizes to Central Muscarinic Mechanism, Life Sci., 41, 2607-2614 (1987)). Muscarinic antagonists are also useful in the treatment of diseases associated with motility alters < Ja of smooth muscle tone, such as irritable bowel syndrome, urinary incontinence, diverticular disease, esophageal achalasia and chronic obstructive disease "Je respiratory tract. U.S. Patent 4,211,867, issued July 8, 1989, refers to the heterocyclic carboxy-idamid derivatives of nitrogen. It has been established that the compounds possess hypoglycemic activity. The patent is < No. 4,414,211, issued November 8, 1983, refers to the heterocyclic derivatives of guanidine. It has been established that the compounds possess hypoglycemic activity.

BRFVF DESCRIPTION OF THE INVENTION The present invention relates to formulated compounds "Where X is NR4R5, (C1-C10) alkyl or (C3-C10) cycloalkyl, wherein said (C3-C10) cycloalkyl may be optionally substituted with one or three solvents, preferably one to two substituents, independently selected from the group consisting of -0R6, (C1-C4) alkyl. oxo and a ketal "Je formula -0- (CH2) n-0-; n is an integer from one to three; rn is an integer from one to three; p is a whole number «Je one to three, - Y is N or CH; Z is NR7 R8, (C3-C10) cycloalkyl, (C1-C10) alkyl, pyridyl or phenyl; wherein said phenyl or (C3-C10) cycloalkyl may be optionally substituted with one or three solvents, preferably one of substituents, independently selected from the group consisting of (C1-C6) alkyl, halogen, hydroxy, alkoxy (C1) -C6), amino, (C1-C6) alkylamino and trifluoromethoxy; R2 is phenyl optionally substituted with one to three constituents, independently selected from the group consisting of (C1-C6) alkyl, halogen, hydroxy, alkoxy (Cl-C6), amino, alkylamino (C1-C6), -CF3, -CN, -COR6, NHCOR6 and trifluorometide i; R3 is phenyl optionally substituted with one to three substituents, preferably one to two substituents, independently selected from the group consisting of (C1-C6) alkyl, halogen, hydroxy, (C1-C6) alkoxy, amino, (C1-C6) alkylamino, dialkylamino (C1-C6), CF3 and trifluoromethoxy; R4 and R5 are independently (C1-C6) alkyl or R4 and R5 together form with the nitrogen atom to which they are attached, a saturated heterocyclic ring of five to nine elements, wherein one of the ring atoms may be optionally substituted with a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, where said saturated heterocyclic ring of five to nine elements can be optionally replaced by one to three substituents, preferably one to two substituents, independently selected from the group formed by -OR6, (C1-C4) alkyl, oxo and a ketal of formula -0- (CH2) rn-0-; with the proviso that said substituted heterocycles are not substituted with hydroxy or a ketal. adjacent to a heteroatom; R6 is hydrogen or (C1-C6) alkyl; and R7 and R8 are independently (C1-C10) alkyl or R7 and RB together form with the nitrogen atom to which they are attached a saturated heterocyclic ring of five to seven elements, wherein one of the ring atoms canIt may be optionally replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, where said saturated five- or seven-membered heterocyclic ring may optionally be substituted with one to three substituents, preferably one to two substituents, independently selected from the group formed by -0R6, (C1-C4) alkyl, oxo and a ketal of formula -0- (CH2) p-0-; with the proviso that said substituted heterocycles are not substituted with hydroxy or a ketal at position two; and the pharmaceutically acceptable salts thereof. The present invention also relates to the pharmaceutically acceptable acid addition salts of the compounds of formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention mentioned above are Those which form non-toxic acid addition salts, that is, salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, phosphate, acid salts, < Jo, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, benzoate, methanesulfonate, ethanesulphonate, benzenesulphonate, p-toluenesulfonate and patoate (ie, 1,1'-methylene- bis- (2-hydroxy-3-naphthoate)] The invention also relates to the addition salts of the base of formula I. The chemical bases which can be used as reactants for preparing pharmaceutically acceptable base salts. those compounds of formula I which are acidic in nature, are those which form non-toxic base salts with said compounds.The said non-toxic base salts include, but are not limited to, those derived from pharmacologically acceptable cations, such as cations of alkali metals (eg, potassium and sodium) and alkaline earth metal cations (eg, calcium and magnesium), ammonium and water-soluble amine addition salts, such as N-rnethylglucamine (egl? mine) and alkanolammonium inferi or and other basic salts of pharmaceutically acceptable organic amines. The above heterocyclic ring systems described with X and Z include, but are not limited to, pyrrolidine, piperidine, thiomorpholine, hexamethyleneimine, morpholine, tetrahydrooxazine, thiomorpholine, tetrahydrodiazine, piperazine, oxazolidine, thiazolidine, pyrazolidine, tetrahydrodiazepine, tetrahydrooxazepine, tetrahydrothiazepine, perhydrodiazocine, perhydrodiazocine, perhydroazonin and perhydrothiazin. The compounds of the invention include all stereoisomers and all optical isomers of formula I (for example, the R and S enantiomers) and their racemic and diastereomeric mixtures. The compounds of the invention include all tautomeric and geometric isomers. Preferred compounds of the invention are compounds of formula I wherein: Z is pyridyl or phenyl, optionally substituted with one to three substituents independently selected from the group consisting of C1-C6 alkyl), halogen, hydroxy, alkoxy (C1-C6), amino, alkylamino (C1-C6), dialkylamino (C1-C6) and trifluoroalkoxy; X is NR4R5 and R4 and R5 together form with the nitrogen atom to which are attached a saturated heterocyclic ring of five to nine elements, selected from piperidine, pyrrolidine, thionroline, hexa ethylenimine, morpholine, thiazolidine and 1,2-tetrahydrooxazine; R2 is phenyl optionally substituted by halogen, hydroxy or methoxy; and R3 is phenyl optionally substituted with one or two substituents independently selected from the group consisting of (C1-C6) alkyl, (C1-C6) dialkylamino, and trifluoroalkoxy. The most preferred compounds of the invention are the compounds of formula Idonde: X is an optionally substituted heterocycle selected from piperidine and 1,2-tetrahydrooxazine; R2 is phenyl optionally substituted with halogen, hydroxy or methoxy; and R3 is phenyl substituted with one or two substituents halogen, hydroxy, (C1-C6) alkoxy, amino, (C1-C6) alkylamino, dialkylamino (C1-C6) and trifluoroalkoxy. The most preferred compounds of the invention are those wherein: R 2 is phenyl substituted in the 4-position of the phenyl ring with fluorine or methoxy; and R3 is phenyl substituted with two substituents independently selected from (C1-C6) alkyl, halogen, hydroxy, (C1-C6) alkoxy, and trifluoroalkoxy. The most preferred compounds of the invention are those formula I wherein X is piperidine substituted at the 2-position with alkyl (Cl-C4) and R3 is 2,6-dimethyphenylene. Specific examples of preferred compounds of formula I include the following: N-C (2,6-dimethyl-phenyl) ~ (4-fluoro-phenyl) o) -rnenyl] -2-methyl-N'-phenyl-piperidine-1-carboxamidine; N- (4-fluoro-phenyl) -2-methyl-N'-C (2-methyl-piperidin-1-yl) -phenylimino-methyl-benzamidine; N- (4-fluoro-phenyl) -2-methyl-N '- (Cl, 2-oxazinan-yl-phenylimino-methyl) -benzamidine; N- (4-fluoro-phenyl) -2-methyl-N'-C (2-rnethyl-piperidin-1-yl) -o-tol-1-imino-rnethyl] -benzamidine, - N- (4- fluoro- phenyl) -N'-C (4-hydroxy-2-methyl-piperidin-1-yl) -phi-limino-methyl] -2,6-dimethyl] -benzami ina; N- (4-f luoro-phenyl) -2,6-dimethyl-N'-C (2-rnethyl-piperidin-1-yl) - (pyridin-3-yl-methyn-benzamidine; 3- phenyl imino- 3-C 2 -methi 11 piperi din-1-yl-lo-tolyl-propenyl) - (4-fluoro-phenyl) -amin; (3-phenylimino-3-Cl, 2.] Oxasinan-2-yl- o-tolyl-? ropenil) - (4-fluoro-phenyl) -amine, (3-phenylimido or ~ 3-Cl, 2] oxazinan-2-yl-lo-tolyl-? ropenil) - (4-methoxy-phenyl) ) -amin, - NC-cyclopropyl imino- (2-methyl-piperi-1-yl) -methyl-1-N'-4-fluoro-phenyl) -2,6-dimethyl-benzamidine, -N-cyclopropyl-quinoline-Cl, 2-oxazinan-2-ethyl-methyl-N '- (4-fluoro-phenyl) -2,6-dirnethyl-benzamidine; N-Cyclopropylimino- (1-methyl-cyclohexyl) rnethyl) -N '- (4-f luoro-phenyl) -2-rnethylbenzamine; and (3-cyclopropylimino-3-Cl, 2-oxazinan-2-yl-l-o-tolyl-propenyl) - (4-fluoro-phenyl) -amine. Other compounds of the invention include: N-phenyl-N '- (phenylimino-pyrrolidin-1-yl-metii) -benza idine; N-phenyl-N '- (phenylimino-piperidin-1-yl-methyl) -benzarnidi a; N-phenyl-N '- (phenylimino-thiomorpholin-4-ethyl-ethyl) -benzamidine; N, N-diet i i-N '-phenyl-N "- (phenyl-phenylalanine-methylene) -guanidine; N- (4-fluoro-phenyl) -N '- (phenyl-1-imino-pyrrolidin-1-yl-methyl) -benzamidine; N- (4-rnetoxy-phenyl) -N '- (phenol-1-imino-rol-din-l-yl-methyl) -benzamidine; N ~ (4-chloro-phenyl) -N '- (phenyl imino-pyrrole idin-1-yl-methyl) -benzamidine; N- (azepan-l-yl-phenylimino-methyl) -N'-phenyl-benzamidine; N ~ (azepan-l-yl-phenylimino-methyl) -N '- (4-rnetoxy-phenyl) -benzamidi a; N- (azepan-l-yl-phenylimino-methyl) -N '- (4-fluoro-phenyl) -benzamidine; 2-ruthen-N-phenyl-N '- (phenylimino-pyrrolidin-1-methyl) -benzamidine; N- (Azocan-1-yl-phenylimino-methyl-N '-pheni 1-benzyl idine; N- [(2-methyl-piperidin-1-yl) -phenylimino-rnethyl] -N'-phenyl-benzarnidine; NC ( 3 ~ rnethyl-piperidin-1-yl) -phenyl-rnin-1-nitnet] -N '-f-enyl-benzamidi a; NC (4-hydroxy-piperidin-1-yl) -phenyl-n-1-methy] -2-methyl-N' - phenyl-benza idine; N- (4-fluoro-phenylimino) -pyrrolidin-1-methyl-N'-phenyl-enzamidi a; N-C (4-fluoro-phenylimino) - (4-hydroxy-piperidin-1-yl) -methyl] -2-rnethyl-N'-phenyl-benzamidine; 2-chloro-N-phenyl-N '- (phenylimino-pyrrolidin-1-yl-methyl) -benzami ina; N- (2,6-demethi-phenyl) • - feni limino-meti 1 l-N '-phenyl-pyrrolidin-1-carboxyamine; N ~ C2-methy1-piperidin-1-yl) -feni limino-methy1-N '-phenyl-benzamidine; N- (aze-an-1-yl-phenylimino-methyl-N '- (4-fluoro-phenyl) -2-methyl-1-benzamidine; NC (4-fluoro-phenyl) -N'-C (2-fluoro) - phenylimido) - (4-hydroxy-pi peri din-l-yl) -methyl-1, 2-methyl-N'-phenyl-benzamidine; NC (2-chloro-phenyl) - (4-fluoro-phenyl) -methyl 1-2 -methyl-N'-phenyl-piperi di nl -carboxyamine, - NC (3-hydroxy-? iperidin-1-yl) -phenylimino-metell-N'-f eni 1 -benza-idi; NC (2-fluoro-phenyl) -phenyl-inino-methyl-lN'-phenyl-pi r rol i 1- 1-carboxyamine; NC (4-fluoro-phenyl) -2-methyl-piperidin-1-yl) -pyridin-4 -ili i no) -meti 11 -benzamidin; N - (Cl, 2 loxazinan-2-yl-phenyl-irnino-methyl) -N'-phenyl-benzamidine; N-C (1,4-dioxa-8-aza-spiroC4.5ldec-8-yl) -phenylimino-methyl l-N '-phenyl benzamidine; N-C (4-fluoro-phenyl) -2-meth i] -benzamidine; N- (4-fluoro-phenyl) -N '-C (4-fluoro-phenylimino) - (2-rneti-1-piperidin-1-yl) -methyl-1-, 6-dimethyl-1-benzamine; 2,6-difluoro-N- (4-fluoro-phenyl) ~ N'-C (2-metii-pi peri-1-yl) -phenyl imino -met. i i) -benzamidine; 2,6-dichloro-N- (fluoro-phenyl) -N'-C (2-rnethyl-pipe-ridin-1-yl) -phenylimino-rnetill-benzamidine; N-C (4-chloro-phenylimino) - (2-methyl-piperidin-1-yl) -rnenyl-N'- (4-fluoro-phenyl) -2,6-dimethyl-β-mzarnidine; N- (adamantan-l-yl-phenyl-non-methyl) -N '- (4-fluorophenyl) -2-rnethyl-benzamidine, NC (2,6-dimethyl-piperidin-l-yl) -phenylimino-metill-N '- (4-fluoro-phenyl) -2,6-dimethyl-benzamidine; N-Caze? An-1-yl- (4- f luo phenyl imino) -methyl-N '- (4-f luoro-phenyl) -2,6-dimethyl-benzamidine; N-C (4-fluoro-phenyl) -N'- (4-fluoro-phenyl-imino) -Cl, 2-xazinan-2-yl-methyl-11-2,6-dimethyl-benzamine; 2, 6-fluoro-NC (4-fluoro-phenyl) -N'-C (4-f luoro-phenylimino) - (2-methyl-piperidin-1-yl)] -methyl-benzamy in, - NC (2,6-dimethy-piperidin-1-yl) - (4-fluorophenyl imino) -methyl) -1 -2,6-di f luoro-N '- (4-phenyl) benzamine; N- (azepan-l-yl-phenylimino-methyl) -N '- (4-f luoro-phenyl) -2,6-dimethyl-benzamidine; N-C (2,6-dimethyl-piperidin-1-yl) - (4-f-luoro-phenyl) -2,6-di-ethyl-benza idin; NC (2,6-dirnethyl-piperidin-1-yl) -phenylimino) -methyl-2,6-di-fluorou-N '- (4-fluorophenyl) -benzamyne, - N- (azepam) 1 -i 1- feni limino-meti 1-2, 6-di f luo ro-n '- (4- f luoro-phenyl) -benzamidine; NC azepane-1-yl- (4-fluoro-phenyl imino) - methyl] -2,6-difluoro-N '- (4-fluoro-phenyl) -benzamidine; NC (2-ethyl-piperidin-1-yl) -phenylimino-methyl) l-N' - (4-f 1 uo rof eni 1) - 2, 6 - di met i 1 - benzarni di na; N-C (2,6-dimethyl-piperidin-1-yl) -phenylimino-methyl) 1-N '- (4-f-luoro-phenyl) -2,6-dimethyl-benzamidin; N- (4-methoxy-phenyl) -2-methyl-N'-C (2-rnethyl-N "-Cometyl-1-piperidin-1-yl) -phenyl-irnino-rnetyl-benzazidine; N- (4- fluoro- phenyl) -2,6-dimethyl-N '- (Cl, 2-oxazinan-2-yl-phenylimino-methyl) -benzamidine; N- (4-fl-o-phenyl) -N'-C (3-hydroxy) piperidin-l-iD-feni limino-methyl 1-2, 6-dimethylbenza idine; N- (4-fluoro-phenyl) -2,6-dimethyl-N'-C (4 -oxo-pi pri di nl -yl) phenylimino-methyl-benzamidine; NC (4-ami no-feni limi.no) - (2-methyl-piperi din-l-yl) -methyl l-N '- (4-fluoro-phenyl) -2 , 6-dimethyl-benzamidin; N- (4-f luoro-phenyl) -2,6-di-ene i-N'-C (2-metii-4-oxo-piperidin-1-yl) -phenimino-met 1-benzamidine; N- (4-fl-o-phenyl) -N'-C3-hydroxy-piperidinyl-1-yl) -phenyl imino-methyl] -2-methi-1-enzamidine; N- (4 -rhetoxy-phenyl) -2,6- < Jirnetil-N '- (Cl, 2-oxazinan-2-yl-phenylimino-methyl) -benzamidine; N- (4-hydroxy-phenyl) -2,6-dimethyl-N '~ (2-methyl-piperidin-1-yl) -phenyl imino-methyl) -phenylimino-methyl-11-benzamidine; N- (azepan-l-yl-phenylimino-methyl) -N '- (4-methoxy-phenyl) -2,6-dirnethyl-benzarnidine; N- (4-f.l? OrO-phenyl) -2-metii-N'-C (4-oxo-? Iperidin-l-iD-phenylimino-methyl-benzamidine; N- (4-fluoro-phenyl) -2-rnethyl-N'-C (2-rnetii-4-oxo-pi peri-din-1-yl) -phi-limino-methyl-11-benzamidine; N-C (3-amino-phenyl) o) - (2-methyl-1-piperidin-1-yl) -methyl] -N '- (4-fluorophenyl) -2,6-dimethyl-benzamidine; N- (4-f 1 uo rof eni 1) -N '- C (4 - hi d rox i -? .i pe ri di n- .1. - i 1 -feni limino-meti 11-2, 6-dimethyl-benzamidin; N- (4-fluoro-phenyl) -N'- 4-hydroxy-2-metii-pi pe ridi nl-il) -phenylimino-methyl-2/6-dirnethyl-benzarnidine; N-C (3 -ami non-phenyl imino) - (2-methyl-piperi din-1-yl) -methyl 1-2, 6 -dimethyl-N '- (4-trifluoromethoxy-phenyl) -benzamidine; 2,6-dirnethyl-N-C (2-methyl-piperidin-1-yl) -phenylimino-netii] -N '- (4-tri-fluorometho-phenyl) -benzamy a; N- (4-fl-oro-phenyl) -2,6-dimethy-N '- (rnorfolin-4-yl-phenylimino-metii)] -benzamidine; N ~ (4-f luoro-phenyl) -2,6-dimethyl-N'-C (2-methyl-piperidin-yl-yl) -m-tolylimino-methyl)] -benzarni «Jina; N- (4-f: luoro-phenyl) -N'-C (3-f-1-pyrrolidinyl) - (2-methyl-? Iperidin-1-yl) -metill-2,6-dirnethyl-benzarnidine; N- (2-chloro-phenylimino) - (2-meth i 1 -piperidin-1-yl) -methyl-l N '- (4-f luoro-phenyl) -2-methyl-benzamidin; N- (4-fluoro-phenyl) -N'-C (2-rnetoxy-phenyl-1-yl) - (2-rnethyl-piperidin-1-yl) -methyl] -2-methyl-benzamidine; N- (4-fluoro-phenyl) -N-C (3-methoxy-phenyl imino) - (2-methyl-piper-ri-din-1-yl) -methyl-1-2,6-dimethyl-benzamidi. na N- (4-fluoro-phenyl) -2,6-dimethyl-N'-C (2-methyl-piperidin-1-yl) -o-tolylimino-ethyl) -1-benzamidine; N- (2-chloro-phenyl imino) - (2-methyl-1-piperidin-1-yl) -methyl] -N '- (4-fluoro-phenyl) -2,6-dimethyl-en-aminidane; (3-phenylimino-3-pyrrole and din-1-yl-phene-1-propenyl) -phenylamine; (3-phenylimino-3-pyrrolidin-1-yl-phenyl-propenyl) -phenylamine; (3-phenylamino-3-thiazolin-3-yl-l-phenyl-phenylpenny) -feni lami a; (3-phenylamino-3-C2-rnetillpiperidinyl-1-l-C2-chloro-phenyl-1-ylenyl) - (4-fluorophenyl) -amine; (3-C4-fluorophenylimino] -3-C2-rnetillpiperidin-1 -i1- 1-o-tolyl-β-pentyl) - (4-f-luoro-phenyl) -amine; (3-phenylimino-3-C2-metii] piperidin-1-yl-1-phenyl-propenyl) -phenylimine; (3-cyclohexyl and -no] -3-C-1,2-loxazinan-21-yl-1-o-tolyl-propenyl) - (4-fluoro-phenyl) -amine; N- Cichlohexyl-imino- (1-methyl-cyclohexyl) -rnethyl] -N '- (4-fluoro-phenyl) -2-methyl-benzamidine; N-Cyclohexylimino- (2-rnethyl-piperidin-1-yl) -methyl] -N '- (4-fluoro-phenyl) -2,6-dimethyl-benzamidine; N-C cyclohexyl imino- (2-rneti 1-piperidin-1-yl) -rnethyl) -methyl l-N '- (4-fluoro-phenyl) -2-methyl-benzamidine; N- C sec -butyl imino- (2-methyl-piperi di n-l -i 1) -rneti 1 l-N '- (4-fluoro-phenyl) -2,6-di-rnet. i 1 benzamidi na; N- (4-fl-o-phenyl) -N'-ieipropyl-2- (2-methyl-1-piperidin-1-yl) -methyl-1-2,6-dimethyl-benzamidine; 3-cyclohexyliminol-3- (2-methyl-piperidin-1-yl) -l-o-tol-1-propemyl] - (4-f-luoro-phenyl) -amine; N- (adamantan-l-cyclohexylimino-rnethyl) -N '- (4-fluoro-phenyl) -2-methyl-benzamidine; N-Cyclobutylimino- (2-rneti? -piperidin-1-yl) -ethyl-N '- (4-fluoro-phenyl) -2,6-dimethyl-benzamidine; N- Cyclopropyl imino- (2-met yl-piperidin-1-y1) -methyl 1-N '- (4-f luoro-phenyl) -2-benzarnidine; N-cyclopro? -limino- (2-methyl-piperidin-1-yl) -methyl 1-N '- (4-methoxy-phenyl) -2,6-dimethyl-benzamidine; N-C-cyclopropylmethyl-imino- (2-methyl-piperidin-1-yl) -methyl] -N '- (4-fluoro-phenyl) -2,6-dimethyl-benzamide; (3 ~ cyclopro? .il imino-3-C.1, 2] oxazinan-2 ~ il-l-phenyl-propenyl) - (4-fluoro-phenyl) -amine; N-Calylirnino- (2-methyl-pipe ridin-1-yl) -rnenyl l-N '- (4-fluoro-phenyl) -2,6-dirnethyl-benzamidine; N- (4-fl-o-phenyl) -2,6-dirnethyl-N '-C (2-rnethyl-piperidin-1-yl) - (morpholin-4-yl-irnino) -methyl-benzamidine; N- (4-fluoro-phenyl) -2,6-dimet i lN'-C (2-methi.1-pi? Eridin-1-yl) - (piperi in -1-yl-irnino) -rneti 11- benzami ina; and N ~ (4-fluoro-phenyl) -2,6 ~ dimethyl-N '~ C (2-methyl-cyclo? ro? -limino) - (2-methyl-piperidin-1-yl) -methyl-benzamidine.

The present invention also relates to a pharmaceutical composition for the treatment or prevention of a disease or disorder, treatment or prevention of which it can be performed or facilitated by reinforcement of the cholinergic neurosynthesis in a mammal, comprising a It is effective for the binding to a muscarinic receptor of a compound of formula I or a pharmaceutically acceptable salt of the ism and a pharmaceutically acceptable carrier. The present invention also relates to a method for the treatment or prevention of a disease or disorder, treatment or prevention of which can be performed or facilitated by the reinforcement of cholinergic neurotransmission in a mammal, which comprises the administration to said mammal of a an effective amount for the binding to a muscarinic receptor of a compound of formula I or a pharmaceutically acceptable salt of the ism. The present invention also relates to a pharmaceutical composition for the treatment or prevention of a disease or disorder, treatment or prevention of which can be performed or facilitated by reinforcement of cholinergic neurotransmission in a mammal, which comprises administering to said mammal a The amount of a compound of formula I or a pharmaceutically acceptable salt thereof which is effective for the treatment or prevention of said disorder. The present invention also relates to a method for the treatment or prevention of a disease or disorder, treatment or prevention of which may be performed or facilitated by the reinforcement of cholinergic neurotransmission in a mammal, comprising the administration to said mammal of an amount of a compound of formula I or a pharmaceutically acceptable salt <Jel itself that is effective for the treatment or prevention of such disorder. The present invention also relates to a method for the treatment, prevention or diagnosis of a disease or disorder selected from the group consisting of psychotic disorders, pain, sleep disorders, «Jepression, disease < Alzheimer's disease, tardive dyskinesia, Pick disease, chorea "Je Huntington, Friedrich's ataxia, Gilbert de la Tourette's disease, Down syndrome, lack of attention disorder, multi-hyphatic dementia, and cognitive decline related to the disease. (ARCD) in a mammal, which comprises the administration to said mammal, including the human being, that needs "said treatment, prevention or diagnosis, of a quantity of compound" according to claim 1 effective in the treatment , prevention or diagnosis of said disorder. The present invention also relates to a pharmaceutical composition for the treatment or prevention of a disease or disorder selected from the group consisting of psychotic disorders, pain, sleep disorders, depression, Alzheimer's disease, tardive dyskinesia, Jad de Pick disease, Korea "Je Huntington, Friedrich's ataxia, Gilles de la tourette's disease, Down's syndrome, attention deficit disorder, multi-hyphatic dementia, and cognitive decline related" Ja with e «Jad (ARCD) in a mammal, comprising a quantity of a compound according to claim 1 effective in the treatment, prevention or diagnosis of said disorder and a pharmaceutically acceptable carrier. Unless otherwise indicated, the alkyl and alkenyl groups recited herein, as well as the alkyl moieties of the other groups mentioned herein (eg, alkoxy), may be linear or branched and may also be cyclic ( for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) or can be linear or branched and contain cyclic radicals. Unless otherwise indicated, halogen includes fluorine, chlorine, bromine and iodine. The compounds of formula I contain olefin or imine bonds and can subsequently exist in cis or trans form. This invention relates to all isomers and to all stereoisomers of compounds of formula I and to mixtures thereof. The phrase "a ketal of formula -o- (CHa)" - 0- ", when used in the present, refers to a spiro group which may be added to a ketone in the presence of an acid catalyst and a glycol. . "Reinforcement of cholinergic neurotransmission", when used in the present, refers to an improvement in the neuronal process by which acetylcholine is released. It is a presynaptic cell by excitation and crosses the synapse to stimulate or inhibit the postsynaptic cell. The compounds of the invention also function by increasing the cholinergic response by miniaturizing the action of acetylcholine on cholinergic receptors. When "Jo X is NR RS and R and R" together they form a heterocyclic ring of three to nine elements optionally substituted and when Z is NRvRβ and T and Rβ together form an optionally substituted heterocyclic ring saturates Jo from five to seven elements, any An expert in the technique will recognize that the following rings are included in these definitions.

HETEROCICLOS OF 6 ELEMENTS 7 ELEMENTS MONOCICLIC HETEROCICLES HETEROCICLOS OF 8 ELEMENTS HETEROCICLOS OF 9 ELEMENTS OFTICRTPTION DET LL DQ OF THE INVENTION The compounds of formula I can be prepared according to the methods of schemes 1-5. In the reaction and discussion diagrams below, fl, m, n, p, Rs », a, R *, Rs, R *, R-T-, ßY and Z, unless otherwise indicated, are as defined for formula I.

SCHEME 1 III 20 N 30 > G S NHÍ I I 35 40 50 SCHEME 2 m fifteen - 30 50 SCHEME 3 C IV VIII il SCHEME 4 fifteen SCHEME 5 N I i XIII The scheme 1 refers to the preparation of the. compounds of formula I, wherein Y is nitrogen and X is NR * Rs, from the compounds of formula III. The compounds of formula III are commercially available or can be prepared by methods available to one of ordinary skill in the art. A compound of formula III is converted to a compound of formula II by sequential reaction of the compound of formula III with a compound of formula X-H and a base in a solvent inert to the reaction followed by reaction with an ammonia. Inert solvents suitable for the reaction include ethers, such as diethyl ether, tetrahydrofuran and diisopropyl ether, acetone or acetonitrile, preferably diethyl ether. Suitable bases include triethylamine, pyridine, diisopropylethylamine, preferably triethylamine. Ammonia can be added in gas form or as a solution in an organic solvent. Suitable organic solvents include alcohols such as ethanol and isopropanol or benzene or toluene. When ammonia is added in the form of a solution, the preferred solvent is isopropanol. The temperature of the reactions during the addition of the X-H reactant can be in the range from about -78 ° C to about 25 ° C, preferably from 0 ° C to about 25 ° C. The temperature for the reaction with the ammonia is in the range from about 0 ° C to about 40 ° C, preferably about 25 ° C.

The compound of formula II is converted to a compound of formula I by reaction of the compound of formula II with a strong base in a solvent inert to the reaction, followed by the addition of a compound of formula C IV The compounds of formula IV can be prepared according to the method described in 3. Heterocyclic Chem., 18, 695 (1981). Suitable bases include sodium hydride, potassium hydride and n-butyllithium, preferably sodium hydride. Suitable solvents include ethers such as tetrahydrofuran, diethyl ether, dimethylformamide, preferably tetrahydrofuran. The temperature during the addition of the strong base can be in the range from about 0 ° C to about 35 ° C, preferably about 25 ° C. The temperature during the addition of the compound of formula IV can be in the range from about -25 ° C. C to about 25 ° C, preferably d is 0 ° C to about 25 ° C. Scheme 2 refers to another form of preparation of the compounds of formula I, wherein Y is nitrogen and X is NR * Ra from the compounds of formula III. A compound of formula III is converted to a compound of formula V by the sequential reaction of the compound of formula III with a compound of formula X-H and a base in a solvent inert to the reaction, followed by reaction with a compound of formula H VI Inert solvents for the reaction include ethers such as diethyl ether, tetrahydrofuran and diisopropyl ether, acetone or acetonitrile, preferably diethyl ether. Appropriate bases include triethylamine, pyridine, diisopropylethylamine, preferably triethylamine. The compound of formula VI is preferably dissolved in a small amount of the solvent inert to the reaction and added dropwise to the reaction, after it has been completed with the compound of formula X-H. The compounds of formula VI ee can be prepared according to the methods described in Eur. 3. Med. Chem., Chem. Ther., 12, 365 (1977) and fiustralian 3. Chem., .2225 (1977) The temperature of the reaction during the addition of the XH reactant may be in the range from about 7B ° C to about 25 ° C, preferably from 0 ° C to about 25 ° C The temperature for the reaction with the compound of formula VI is in the range of from about -10 ° C to about 80 ° C, preferably from about 0 ° C to about 40 ° C (ie, the boiling point of the preferred solvent). The compound of formula V is converted to a compound of formula I by reaction with a compound of the formula RaNHa in a solvent inert to the reaction at a temperature of from about 25 ° C to about 100 ° C, preferably at about 100 ° C. Suitable solvents include (1,4) -dioxane, tetrahydrofuran, dimethyl forrnarnide, acetonitrile or t-butanol, preferably (1,4) -dioxane or t-butanol. Scheme 3 refers to the preparation of the compounds of formula I, wherein Y is nitrogen and X is NR * RS, from the compounds of formula IV. The compounds of formula IV ee can be prepared according to the methods described in 3. Heterocyclic Chem., 18, 659 (1981). The compounds of formula IV are converted to the compounds of formula VIII by sequential reaction of the compound of formula IV in a solvent inert to the reaction with thiocyanate, followed by reaction with compound of formula Z-NHa. Suitable thiocyanates include sodium thiocyanate or potassium thiocyanate, preferably sodium thiocyanate. Suitable solvents include acetone, ethers (such as tetrahydrofuran) and acetonitrile, preferably acetone. The temperature for the reaction with the thiocyanate is in the range from about -35 ° C to about 10 ° C, preferably 0 ° C. The temperature of the reaction with the compound of the formula Z ~ NHa is in the range from about -35 ° C to about 35 ° C, preferably about 25 ° C. Variations of the aforementioned reaction can be found in Goerdeler, et.al, Chem. Ber., 101, 3475 (1968). The compound of formula VIII can be converted to a compound of formula VII by reaction with a methylating agent in a solvent inert to the reaction. Suitable methylating agents include trimethyloxo io methylotetra luoroborate iodide or methyl trifluoromethane-fonate, preferably methyl iodide or trimethyloxonium tetrafluoroborate. Inert solvents for the reaction include rnetylene chloride, 1,2-dichloroethane or acetone, preferably acetone or methylene chloride. The aforementioned process temperature may be in the range from about 0 ° C to about 90 ° C, preferably from 25 ° C to about 60 ° C. The compound of formula VII can be converted into a compound of formula I by reaction with a compound of formula X-H in an inert solvent for the reaction. Inert solvents for the reaction include (1,4) -dioxane, acetonitrile, t-butanol or dimethylformamide, preferably (1,4) -dioxane. The aforesaid reaction temperature is in the range from about 25 ° C to about 180 ° C, preferably 100 ° C (ie, the boiling point of the preferred solvent). On the other hand, a compound of formula VII can be converted into a compound of formula X-H in the presence of silver nitrate and a base in a solvent inert to the reaction, in the dark. Suitable bases include triethylanine, pyridine, diisopropylethylamine, preferably triethylamine. Inert solvents suitable for the reaction include acetonitrile, methylene chloride or 1,2-dichloroestane, preferably acetonitrile. The aforesaid reaction temperature is in the range of from about -15 ° C to about 60 ° C, preferably from about -15 ° C to about 25 ° C. Variations of the aforementioned reaction can be found in Boisin et al., 3. Org. Chem., 38, 1591 (1973). On the other hand, a compound of formula I can be prepared directly from a compound of formula VIII by reaction with a compound of formula XH and l- (3-dimethylaminopropyl) -3-ethylcarbodiirnide hydrochloride (EDCI) in an inert solvent for Suitable reactions include dimethylformamide, tetrahydrofuran, diethyl ether or methylene chloride, preferably dimethylformamide or tetrahydrofuran. The aforesaid reaction temperature is in the range from about 0 ° C to about 35 ° C, preferably about 25 ° C. Variations of the aforementioned reaction can be found in fitwal et al. Tetrahedron Letters, 30, 7313 (1989). Scheme 4 refers to the preparation of the compounds of formula I, wherein Y is -CH and X is NR * RS, from the compounds of formula XII. The compounds of formula XII are commercially available or can be prepared by methods well known to those skilled in the art. In regard to Scheme 4, a compound of formula XII is converted to a compound of formula XI by reaction with an isothiocyanate of formula Z-C = S in the presence of a strong base in a solvent inert to the reaction. Suitable bases include bis (trirnethylsilyl) amide potassium or bis (trimethylsilyl) amide, potassium or sodium bis (trimethylsilyl) amide, lithium disopropylamide, n-butyllithium or sodium hydride, preferably lithium bie (trimethylsilyl) amide. Inert solvents suitable for the reaction include tetrahydrofuran, diethyl ether, methylene chloride or tuelene, preferably tetrahydrofuran. The aforesaid reaction temperature is in the range from about -78 ° C to about 80 ° C, preferably from about -78 ° C to about 25 ° C. The compound of formula XI is converted to a compound of formula X by reaction with a compound of formula R ^ -NHss and a catalytic amount (5-20%) of acid in a solvent inert to the reaction. Suitable acid catalysts are the hydrochloride salt of the Ra-NHa reactant (for example Ra-NHa >"HCL), toluenesulfonic acid or phonosulphonic acid, preferably Ra-NH = -HCL, Suitable inert solvents for the reaction include benzene, toluene or xylene, preferably benzene, The temperature of the aforesaid reaction is in the range from about 50 ° C to about 150 ° C, preferably about 80 ° C, ie, the boiling point of the preferred solvent The reaction is facilitated by removing the water Suitable dehydrating agents include the azeotropic removal of water. of formula X can be converted to a compound of formula IX by reaction with methylating agent in a solvent inert to the reaction Suitable ethylating agents include methyl iodide, trimethyloxonium tetrafluoroborate or methyl tri fluoromethanesulphonate, preferably trimethyloxonium tetrafluoroborate. suitable inert reaction solvents include methyl chloride leno, 1,2-dichloroethane. The temperature of the aforementioned process may be in the range from about -10 ° C to about 30 ° C preferably from OßC to about 25 ° C. The compound of formula IX is converted to a compound of formula I by reaction with a compound of formula X-H in a solvent inert to the reaction. Appropriate inert solvents for the reaction include 1,4-dioxane, acetonitrile, t-butanol or dimethylformamide, preferably (1,4) -dioxane. The aforesaid reaction temperature is in the range from about 25 ° C to about 180 ° C, preferably 100 ° C (ie, the boiling point of the preferred solvent). On the other hand, a compound of formula IX can be converted into a compound of formula I with reaction of formula XH in the presence of silver nitrate and a base in a solvent inert to the reaction, in the dark, the appropriate bases include triethylamine, pyridine, diieopropylethylane, preferably triethylamine. Suitable inert reaction solvents include acetonitrile, methylene chloride or 1,2-dichloromethane, preferably acetonitrile. The aforesaid reaction temperature is in the range from about -15 ° C to about 60 ° C, preferably from about 0 ° C to preferably 25 ° C. Scheme 5 refers to the preparation of compounds of formula I from compounds of formula IV. The compounds of formula IV can be prepared according to the methods described in 3. Heterocyclic Chem., 18, 659 (1981). As regards scheme 5, a compound of formula IV is converted to a compound of formula XIV by reaction with ammonia in a solvent inert to the reaction. Suitable inert reaction solvents include alcohols, such as ethanol, isopropanol or butanol, benzene or toluene, preferably toluene. Ammonia can be added as a gas or as a solution in an organic solvent. When the ammonia is added in the form of a solution, the preferred solvent is the solvent that has been used as an inert solvent for the reaction (for example, toluene). The temperature for the reaction is in the range from about 10 ° C to about 0 ° C, preferably about 25 ° C. The compound of formula XIV is converted to a compound of formula XIII by reaction with a compound of formula XC (= 0) -C1, in the presence of a base and of a catalytic amount (5-20%) of 4-dimethylaminopyridine, in an inert solvent p > for the reaction. Suitable bases include triethylamine, diisopropylamine, preferably triethylamine. Suitable inert reaction solvents include methylene chloride, 1,2-dichloroethane or tetrahydrofuran, preferably methylene chloride. The aforesaid reaction temperature is in the range from about 0 ° C to about 50 ° C, preferably about 25 ° C. The compounds of formula X-C (= 0) -C1 are commercially available or can be prepared by the methods of Rost et al., 3 ftrn Pharm. flseoc 46, 290 (1957), as well as with other methods known to those skilled in the art. The compounds of formula XIII can be converted into compounds of formula I by sequential reaction of the compound of formula XIII with a chlorinating agent, followed by reaction with a compound of formula Z-NH ^ in a solvent inert to the reaction. Suitable chlorinating agents include phosphorus oxychloride, phosphorus pentachloride, preferably phosphorus pentachloride. Suitable inert reaction solvents include tetrahydrofuran, methylene chloride or 1,2-dichloroethane, preferably tetrahydrofuran. The temperature of the chlorination step of the aforesaid reaction is from about 100 ° C to about 150 ° C, preferably about 125 ° C. The temperature of the reaction with a compound of formula Z-NH 2 is from about 0 ° C to preferably 50 ° C, preferably about 25 ° C. On the other hand, a compound of formula I can be prepared directly from a compound of formula XIV by reaction with a compound of formula XV in an inert solvent for the reaction. The compounds of formula XV can be prepared according to the method described in 3: Heterocyclic Chern., 18, 659 (1981). Suitable inert reaction solvents include diethyl ether, tetrahydrofuran, methylene chloride, 1,2-dichloroethane, tetrahydrofuran, preferably tetrahydrofuran. The aforesaid reaction temperature is in the range from about -20 ° C to about 80 ° C, preferably about 25 ° C. The compounds of formula I containing a hydroxy radical in X or Z (ie, Z not the phenyl) or both rings, can be prepared from the compounds of formula I in which the radical X and / or Z contain a ketal. The ketal moiety can be introduced into any of the starting materials described in schemes 1-5, which can carry a ketone group or any of the X or Z rings. Anyone skilled in the art will be able to convert the ketal into a alcohol by standard methods. The compounds of formula I containing a hydroxy group in one or both rings Ra or Ra, according to methods known to those skilled in the art. The compounds of formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desired in practice to initially isolate a compound of formula I from the reaction mixture as an unacceptable pharmaceutical salt and then simply convert it to the free base compound by treatment. with an alkaline reagent and subsequently converting the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the basic compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in an appropriate organic solvent such as methanol or ethanol. By carefully evaporating the solvent, the desired solid salt is obtained. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, ie salts containing pharmaceutically acceptable anione, such as hydrochloride salts, hydrobromide. , hydroiodide, nitrate, sulfate or bisulfate, phosphate or phosphate acid, acetate, lactate, citrate, acid citrate, tartrate, bistartrate, succinate, maleate, fumarate, gluconate, sac ato, benzoate, methanesulfonate and pamoate (ie 1.1 -rnetylene-bie- (2-hydroxy-3-naphthoate)] Those compounds of formula I which are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations Examples of such salts include the alkali metal salts and the alkaline earth metal salts and especially the sodium and potassium salts These salts are prepared by conventional techniques. or reagents for preparing the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of formula I described herein. These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can be easily prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations and then evaporating the resulting solution to dryness, preferably under reduced pressure. On the other hand, they can also be prepared by mixing lower alkanolic solutions of the acidic compounds and the alkoxides of the desired alkali metals and then evaporating the resulting solution in dryness in the same manner as above. In any case, stoichiometric quantities of the reactants are used in order to ensure that the reaction is completed obtaining maximum yields of the desired final product. The compounds of this invention will be useful for the treatment of fylzheimer's disease (Efl) or senile dementia of the filzheimer type (DSTfi). In PD, it is seen that the density of Ma receptors decreases, while the density of postsynaptic rt receptors remains unchanged. A muscarinic egonist .selective of the ma. (H) would therefore be effective in the early and advanced stages of AD and would have minimal side effects. These agents may also be useful in other disorders with altered cholinergic neurotransmission, such as in tardive dyskinesia, Pick's disease, Huntington's cores, Friedrich's ataxia, Gilles de la Tourette's disease, Down's syndrome, the disorder of loss of attention (ADD), multi-hyphatic dementia and cognitive decline related to age (ARCD). The compounds of this invention can also be used in combinations with a peripheral anti-muscarinic agent, such as N-methyl-scopolamine, to minimize secondary peripheral effects, in combination with antidepressants such as imipramine for the treatment of cognitive decline and depression associated with AD, in combination with serotonin reuptake inhibitors, such as Zoloft® (brand name), for the treatment of cognitive decline and depression associated with AD; in combination with antipsychotics, such as haloperidol, for the treatment of cognitive decline and the psychosis associated with AD; in combination with anxiolytics, such as diazepam, for the treatment of cognitive decline and anxiety associated with AD; in combination with nicotinic agonists, such as nicotine, in order to stimulate central muscarinic and nicotinic receptors; in combination with neorotrophic factors, such as NGF, in order to maximize cholinergic reinforcement; in combination with agents that slow down or stop AD, co or amyloid inhibitors or tau. These agents can also be useful in the treatment of addictions, such as tobacco (to kick the habit) and for the treatment of glaucoma. The compounds of this invention can offer not only palliative therapy for AD, but can also slow the progression of the disease. In vitro studies have shown that stimulation of the m and m muscarinic receptors with carbacol, a known muscarinic egonist, produces a rapid release of the soluble iloid precursor protein (APP) derivatives (Nitsch et al., Reléase of Alzheimer's A yloid Precursor Derivatives Stimulated by Activation of Muscarinic Acetylcholine Receptors, Science, 258, 304-307 (1992). The formation of highly insoluble peptide Aβ from APP produces arniloidosis, which causes neurotoxicity and the formation of neuritic plaques. The activity of the compounds of formula I for muscarinic receptors can be determined according to the following protocol, which can be obtained through Dr. Tom Bonner (Cell Biology Laboratory, National Institute for Mental Health, Building 36, Room 3A- 17, Bethesda National Institute of Health, MD 20892) Chinese Hamster Ovarian Cells (CH0-K1) Stably Transformed to Express Remedies hurnanoe mrna ptores. Lae cells are maintained in Eagle Modified Dulbecco's Medium containing 10% fetal calf serum and are harvested when confluent by brief incubation in saline solution with C-M ** and without phosphate containing 4 mM EDTA. For ligand binding studies, the cells are homogenized by sonication in distilled water and the membranes are collected by centrifugation (19 minutes at 15,000 x g). Membranes are incubated for 45 minutes at 20-22 ° C with aH-N-methyleneopolarnine (NMS, 0.5-1.0 nM) in 0.25 ml of 20 mM HEPES (N-2-hydroxyethylpiperazine-N '- acid). 2etanesul phonic), 2 M in MgCl 2, pH 7,4. The bound ligand is collected by rapid filtration and quantified by liquid scintillation spectroscopy. The non-specific binding is defined in the presence of 10 μ NMS not labeled. The apparent Ki for the competing ligands is calculated as described by Cheng and Prusoff, Biochem. Pharm., 22, 3099-3108 (1973). Functional responses to the rn2 and p receptors can be determined by measuring the inhibition of cAMP accumulation stimulated by forskolin. The collected cells are preincubated (15 minutes at 20-22 ° C) with 3-isobutyl-1-methyl-xanthine (IBMX, 0.2 mM) and then incubated (10 minutes at 20-22 ° C) in a Krebs solution buffered with HEPES with the test compounds in the presence of 5μM phoskolin. The reaction is stopped by addition of ION acetic acid and the cAMP content of the dried supernatants is determined using a scintillation proximity assay (Amersham). typically giving an inhibition of 60-80% of the cAMP levels stimulated by forskolin. The functional responses at the m, m3 and rna receptors can be determined by measuring increases in the hydrolysis of phosphotidylinositol. The collected cells are preincubated (60 minutes at 37 ° C) in a solution of Krebe tempered with HEPES, with 3H-mionoeitol (ARC Inc., 7.3 μCi / ml). Labeled cells are added to the test compounds and incubated 1 hour at 37 ° C in the presence of 10 mM LiCl. The cells are extracted with chloroform: methanol (1: 2) and the aqueous phase is loaded on ion exchange resin columns DOUEX AG1-X8. Inositol phosphates (mainly IP3) are eluted with formic acid 0, 1 M / ammonium formate and the valuation is made. All compounds of this invention, which were tested with the above receptor assays, have an ECso, in the 8 * and m * receptor assay, of about 1 nM to about 10 μM or less. All the compounds of this invention that were tested, have an ECS, in the m, ma and ms receptor assay, of approximately 10μM or less. The composition of the present invention can be formulated in a conventional manner using one or more acceptable pharmaceutical carriers. Therefore, the active compounds of the invention can be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation. For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients, such as binding agents (eg, pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropylmethylcellulose).; charge materials (for example, lactose, cellulose, microcrystalline or calcium phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium glycolate); The tablets can be coated according to methods known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Said liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives, such as suspending agents (for example, sorbitol syrup, methylcellulose or edible hydrogenated fats); emulsifying agents (for example, lecithin or gum arabic); non-aqueous vehicles (e.g., almond oil, oil esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid). For buccal administration, the composition may be in the form of tablets or lozenges formulated in a conventional manner. The compounds of the invention can be formulated for parenteral administration by injections, including conventional characterization or infusion techniques. The formulations for injection should be present in a unit dosage form, for example, in ampoules or in multi-dose packaging and have a preservative. The compositions may have such forms as suspensions, solutions or emulsions in oil or aqueous vehicles and may contain formulation agents, such as suspending, stabilizing and / or dispersing agents. On the other hand, the active ingredient may be in powder form for reconstitution with appropriate vehicle, eg, sterile pyrogen-free water, before use. Compounds of the invention can also be formulated in rectal compositions, such as suppositories or stopping enemas, for example, containing conventional suppository bases, such as cocoa butter or other glycerides. For intranasal administration or administration by inhalation, the active compounds of the invention are conventionally dispensed in the form of solution or suspension in a spray container that is pressed or pumped by the patient or as an aerosol spray presentation in a pressurized container or nebulizer , with an appropriate propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra-fluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by means of a valve dispensing a measured quantity. The pressurized pack or the nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, of gelatin) for use in an inhaler or insufflator can be formulated with a powder mixture of an inventive compound and an appropriate powder base such as lactose or starch. A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to a human adult medium for the treatment of the above-mentioned disorders (e.g., EA) is 0.1 to 200 g of the active ingredient per unit dose, which could be administered, for example, from 1 to 4 times per day. Aerosol formulations for the treatment of the above-mentioned disorders (for example AD) in the adult human, are preferably established in the form of each medium dose or "puff" of aerosol contains from 20μg to 1000μ of the compound of the invention . The average daily dose with aerosol will be within the range of 100 μg to 10 mg.The administration can be several times a day, for example, 2, 3, 4? 8 times, administering for example, 1.2 or 3 doses each time. In relation to the use of an active compound of this invention with a 5-HT reuptake inhibitor, preferably sertraline, for the treatment of subjects who provide one of the above disorders, it should be noted that these compounds can be administered alone or in combination with pharmaceutically acceptable vehicles, according to the aforementioned routes and that said administration can be carried out in doses unique and in multiple doses. More particularly, the active combination can be administered in a wide variety of different dosage forms, that is, it can be combined with several pharmaceutically acceptable inert carriers in the form of tablets, capsules, pills, tablets, candies, powders, mists, suspensions. aqueous, injectable solutions, elixirs, syrup and others. Such vehicles include solid diluents or filler materials, sterile aqueous media and various non-toxic organic solvents, etc. Also, said pharmaceutical formulations can be sweetened and / or flavored by various agents of the type usually employed for this purpose. In general, the compounds of formula I are present in said dosage forms at a concentration levels ranging from about 0.5% to about 90% by weight of the total composition, ie, in amounts that are sufficient to provide the desired unit dosage and inhibitor of 5-HT reuptake, preferably in sertraline, is present in said dosage forms at concentration levels ranging from about 0.5% to about 90% by weight of the total composition , that is, in amounts that are sufficient to provide the desired unit dosage. The compounds of this invention can exist in different polymorphic forms, ie different crystalline forms. A proposed daily doe of a compound of this invention in the combination formulation (a formulation containing an active compound of this invention and that inhibitor of 5-HT reuptake) for oral, parenteral, rectal or oral administration a human adult medium for the treatment of the above-mentioned traetornoe is from about 0.01 mg to about 2000 rng, preferably from about 200 g of the active ingredient of formula I per unit dose, which can be administered, for example 1 to 4 times a day A pr-opposed daily dose of a 5-HT reuptake inhibitor, preferably sertraline, in the formulation of combinations for oral, parenteral or buccal administration to an average adult human, for the treatment of the above-mentioned disorders , is from about 0.1 ng haeta about 2000 rng, preferably from about 1 mg to about 200 mg of the 5-HT reuptake inhibitor per unit doe, which can be administered, for example 1 to 4 times a day. A preferred doeis ratio of setralin to an active compound of this invention in the combination formulation for oral, parenteral or buccal administration to an average adult human, for the treatment of the above-mentioned disorders, is from about 0, 00005 up to about 20,000, preferably from about 0.25 haeta about 2000. The aerosol combination formulations for the treatment of the above-mentioned disorders in the average adult human are preferably fixed in such a way that each measured dose or "puff" of aerosol contains from about 0.01 μg to about 10000 μg of the active compound of this invention, preferably from about 1 μg to about 10 mg of said compound. The administration can be several times a day, for example, 2, 3, 4? 8 times, administering for example, 1, 2 or 4 doses each time. The aerosol formulation for the treatment of the disorders mentioned above in the average adult human are preferably fixed in such a way that each measured dose or "puff" of aerosol contains from about 0, 01 mg to about 2000 mg of a 5-HT reuptake inhibitor, preferably sertraline, preferably from about 1 mg to about 200 g of sertraline. The administration can be several times a day, for example, 2, 3, 4 or 8 times, administering for example, 1, 2 or 3 doses each time. As previously mentioned, a 5-HT reuptake inhibitor, preferably sertraline, in combination with the components of formula I, readily adapts to therapeutic use as antidepressant agents. In general, these antidepressant compositions containing a 5-HT reuptake inhibitor, preferably sertraline, and a compound of formula I, are usually administered in doeis ranging from about 0.01 mg to about 100 mg per kg of body weight per day of a 5-HT reuptake inhibitor, preferably sertraline, preferably from about 0.1 mg to about 10 mg per kg of body weight per day of sertraline, with from about 0.001 mg to about 100 mg per kg of weight per day of a compound of formula I, preferably from about 0.01 mg haeta to about 10 mg per kg of body weight per day of a compound of formula I, although variations will be necessary depending on the condition of the subject to be treated and of the chosen administration route. The following examples illustrate the preparation of the compounds of the present invention. The commercial reagents were used without further purification. Melting points are given without correction. The NMR data are given in parts per million (d) and are related to the deuterium stabilization signal of the solvent of the mueetra. Specific rotations were measured at room temperature using the D line of sodium (589 nm). The ambient temperature is 20-25 ° C. The mass spectrum (MS) and the high resolution mass spectrum (HRMS) were performed using electron impact conditions (El), 70 ev), chemical ionization (Cl) or fast atom bombardment (FAB). Chromatography refers to column chromatography carried out using conditions of 32-63 μn of silica gel and carried out under nitrogen pressure (flash chromatography). The purification of the final compounds was carried out using buffered silica gel prepared in the following manner. A mixture of 125 grams of silica gel and 500,000 KHaP0 4% was stirred for 1 hour and filtered. The collected tarnished silica gel was dried in the air and then dried in an oven at 120 ° C for 48 hours or more.

EXAMPLE 1 Scheme 1 N-phenyl-N '- (phenylimino-pyrrolidin-1-yl-benzamirti na Step Q Intermediate Product of Formula II (Z = phenyl Q. X = pyrrolidine) A solution of pyrrolidine (8.18, 0.115 mol) and triethylamine (11.6 g, 0115 mol) in diethyl ether (29 ml) is added dropwise to a cold (0 ° C) solution of phenylisocyanide dichloride (20 g). , 0 g, 0.115 mol) in diethyl ether (200 ml). After the addition was complete, the mixture was stirred at 0 ° C for 1 hour and then allowed to warm to room temperature (20 minutes) The reaction was filtered and the filtrate was added dropwise to a solution saturated ammonia / isopropanol (600 nl) After 1.25 hours, the excess of ammonium chloride was removed by filtration and the filtrate was concentrated, the residue was redissolved in isopropanol (25 ml) and hydrogen chloride was bubbled ( g) for 5 minutes.After concentration, the pale yellow gum triturated in diethyl ether to give a greyish cabbage solid (24.20 g, 93%) hydrochloride salt.? -I-NMR (DMSO-d * ) d 9.68 (s, lH), 7.59 (s, 2H), 7.43 (m, 2H), 7.30 (, .3H), 3.52 (ma, 4H), 1.93 (ta, 4H, 3 = 6.6 Hz).

Step B Kl-Phenyl-N'- (Phenylimino-oyrrolidin-1-yl-methyl) -benzamine di Sodium hydride (dispersion in 60% mineral oil, 1.1 g, 27.68 mmol) was added to a suspension of the product from step A (free base, 6.25 g, 27.68 mmol) in tetrahydrofuran, THF ( 70 nl) at room temperature. After stirring for 15 minutes, the mixture was cooled to 0 ° C and a solution of benzene-bioxyimidoyl chloride, N-phenyl (prepared according to the method described in 3. Heterocyclic Chem., Lfi, 651 (1981) was added dropwise. ) (3.0 g, 13.84 mmol) in THF (50 ml) The resulting mixture was allowed to warm to room temperature and was stirred for 16 hours (overnight) The reaction mixture was then subjected to reflux After cooling to room temperature, the mixture was filtered and the filtrate was concentrated The residue was dissolved in chloroform and the resulting organic strain was washed with IN hydrochloric acid, followed by brine The organic strain was then dried The yellow solid obtained was dissolved in a minimum amount of acetone and diethyl ether was added.The pale yellow solid obtained was collected by filtration and dried under high vacuum, after which it was filtered and concentrated. or 1.8 grams of crude material The subsequent purification was carried out by recrystallization (isopropanol / diethyl ether) to give the title compound (400 mg, 7%), hydrochloride salt, as an off-white solid. p.f. 246-247 ° C; H NMR 8dmso-d *) 6 10.78 (s, 1H), .20 (s, 1H), 7.75 (sa, 2H), 7.56 (t, 1H, 3 = 7.4 Hz), 7.40-7.47 (m, 4H), 7.11 -7.27 (m, 4H), 7.06 (d, 2H, 3 = 7.5 Hz), 6.84 (d, 2H, 3 = 7.3 Hz), 3.63 (s, 4H) 1.97 (sa, 4H; CIMS EXAMPLE 2 Scheme 2 n- -Fluoro-phenyl-N '- (enylamino-pyrrolidin-1-yl-methyl-bengamidine Step Q Intermediate Product of Formula V (X = pyrrolidine? T Z = R «= Fenilp? A solution of pyrrolidine (0.55 mmol, 6.61 mol) and triethylamine (0.92 ml, 6.61 mmol) in diethyl ether (10 ml) is added dropwise to a cold (0 ° C) solution of phenyl isocyanide dichloride (0.9 ml, 6.61 mol) in diethyl ether (15 ml ml). After 40 minutes, the reaction was filtered. The filtrate was re-cooled to 0 ° C and a solution of methylmerity of carboxymethodic acid benzene (prepared according to the methods described in Eur. 3, Med. Chem., Chim. Ther., 12, 365 (1977)) was added. and Australian 3. Chem., 30.2225 (1977) (.1.0 g, 6.61 mol) in diethyl ether (5 ml) The cold bath was removed and the mixture was heated to reflux for 19 hours. The solids were removed by filtration and the filtrate was concentrated.The residue obtained was washed with diethyl ether giving (1.77 g, 76%) an off-white solid, hydrochloride salt, H-NMR (DMSO-c) d 10.83 (s, lH), 7.60 (t, lH = 7.5 Hz), 7.46 (y, 2H, 3 = 7.7 Hz), 7.18-7.32 (m, 3H), 7.04 (d, 2H, 3 = 7.5 Hz), 6, 87 (d, 2H, 3 - 6.9 Hz), 3.73-3.78 (m, 2H), 3.40-3.57 (m, 2H), 2.58 (S, 3H), 1 , 95-2.11 (m, 4H).

Step B N-Fluoro-phenyl-N '- (phenylimino-pyrrole di-1-yl-met i 1) -benzamidine A mixture of the product of Step A (0.5 g, 1.39 mmol) and p-fluoroaniline (0.330 ml) in dioxane (10 ml) was heated to reflux for 23 hours. The mixture was allowed to cool to room temperature and the reaction was filtered. The title compound (0.453 g, 77%), hydrochloride salt, was obtained as a white solid. P.f 259-260 ° C (dec); H-NMR (DMSO-D *) d 10.68 (s, lh, 9.95 (s, 1H), 7.77 (ea, 2H), 7.57 (t, 1H 3 = 7.4 Hz) 7.42 (t, 2H, 3 = 7.6 Hz), 7.29 (t, 2H, 3 = 8.7 Hz), 7.12-7.23 (rn, 3H), 7.04 (d, 2H, 3 = 7.6 Hz), 6, 77 (d, 2H, 3 = 7.2 Hz), 3.57- 3.64 (m, 4H), 11, 97-1.99 (m, 4H); FABMS CaAHaaFN-: 387 C (M + 1) *, 1003.

EXAMPLE 3 Scheme 3 M-rf ^ -Methyl-n nridon-l-ill-phenylimino-metin-N ^ -fen l -benzaid a Step fl Intermediate Product of Formula VIIT = a = »= Phenyl? A solution of sodium thiocyanate (18.8 g, 0.32 mol) in acetone (400 ml) was added dropwise to a stirred solution of benzenecarboxyimidoyl chloride, N-phenyl (50.0 g, 0.32 g). mmol) in acetone (129 ml) at 0 ° C. After 1 hour, the reaction mixture was filtered (10-20μ) and the filtrate was again cooled to 0 ° C. Aniline (23.7 rnl, 0.232 mol) was added dropwise and the reaction was allowed to warm to room temperature. After 1.5 hours, the formed precipitate was collected by filtration to give a pale yellow solid (49.12 g, 64%). XH-NMR (DMSO-c *) d 10.61-10.88 (m, 1.H), 9, B0-10.21 (m, 1H), 7.40-7.75 (m, 9H), 7.21-7.83 (m, 4H), 6.97-7.15 (m, 2H).

Step B Intermediate Product of Formula VII JZ? Bat = R «- __.__._-« -__-_- > Methyl iodide (6.8 ml, 0.11 mol) was added to a suspension of the product of Paeo A (33.0 g, 01 mol) in methidochloride (450 rnl) at room temperature and the reaction warmed then refluxed for 22 hours. The reaction mixture was then cooled, filtered and the precipitate was collected and dried to give a pale yellow solid (27.7 g, 59%) as the hydrochloride salt. aH-NMR DMSO-d *) d 11.70 (br s, 2H), 7.64-7.71 (m, 6H), 7.51 (t, 3H, 3 = 7.8 Hz), 7.32 -7.43 (m, 4H), 7.05-7.15 (m, 2H), 2.5 (s, 3H).

Step C N-A (2.Methyl-DIDERIDIN-1-yl) -phenylimino-metin-N ^ - (phen-1-benzamidine) To a suspension of the product of Step B (1.00 g, 2.11 mmol) in 1,4-dioxane (20 ml) was added 2-rnethylpiperidine (0.745 ml, 6.33 mmol). The resulting solution was heated to reflux for 20 hours. Then, the solution was concentrated and the residue purified by flash chromatography on silica gel (gradient of 100% methylene chloride to 5% ethanol-methylene chloride) to give the title compound 80.93 G, 17%) hydrochloride salt, as a pale yellow solid. P.f. 219-221 ° C (dec), XH-NMR (DMSO-d-6) d 10.57 (br s, 1H, 9.64 (br s, 1H), 7.69-7.72 (rn, 2H) m , 761 (t, 1H, 3 - 7.7 Hz), 7.43-7.51 (m, 4H), 7.11-7.29 (m, $ H), 6.98 (d, 2H) , 6.74 (d, 2H), 4.51-4.60 (m, 1H), 3.95-4,, 09 (m, 1H) 3.25-3.34 (m 1H), 1 , 40-1.73 (m, 5H), 1.28 (dd, 3H, 3 = 5.3 Hz); CIMS Ca «sHs_ßN * _397 [(M + l) - +, 100].

EXAMPLE 4. Scheme 3 N- (Cl.2] Oxazinan-2yl.phenylimino-methyl) -N '(phenylbenzamidine Step C Triethylamine (0.20 ml, 1.45 mol) was added followed by tetrahydroozanine (prepared according to the methods described in King, H., 3. Chem. Soc. 1942, 432) (0.358 g 2.90 mmol) to a solution of the product of Example 3, Paeo B, free base (0.5 g, 1.45 nmol) in acetonitrile (50 ml) at 0 ° C. A solution of silver nitrate (0.246 g, 1.45 mmol) in acetonitrile (2 ml) was added and, after 10 minutes, it was removed from the ice bath and the reaction was allowed to stir at room temperature in the dark. After 1.5 hours, the mixture was centrifuged (3500 rpm, 10 minutes) and the supernatant was decanted, filtered (45μ) and the purification was concentrated by flash chromatography (gradient of 100% methyl chloride to methanol). methylene chloride) gave the title product (0.524 g, 86%), nitrate salt, as a whitish solid. P.f.l87-190 ° C; H-NMR (DMS0-dA) d 10.90 (EA1H), 10.45 (SA, 1H), 7.70-7.74 (m, 2H), 7.62 (t, 1H, 3 = 7.5 Hz), 7.43-7.52 (m, 4H), 7.10 (d, 2H, 3 = 7.8 Hz). 6.95 (d, 2H, 3 = 7.4 Hz), 6.95 (d, 2H, 3 = 7.4 Hz), 3.82-4.20 (m, 4H), 1.48-1 80 (m, 4H); CIMS C ^ H ^ ^ O: 385 [(11 + 1? *, 100].

EXAMPLE 5 Scheme 3 N- (4-methoxy-phenyl) -2.B-dimethyl-N - [(22-riethyl-DIDeridin-l-yl-phenylimino-methyl] -benzamidine Step fl 'Intermediate Product of FormIV c «« =) -Issenyl methylate: R »0 2,6-dimethylphenyl) A pure mixture of 2,6-dirnethylbenzamide, N-4-methoxyphenyl (6.60 g, 25.85 mol) and phosphorus pentachloride (5.38 g, 25.85) was heated to 120 ° C. The obtained solution was stirred for 20 minutes. Toluene was added and the mixture was concentrated (two vecee). The oil obtained was immediately used as such in the next step.

Step F Intermediate Product of FormVIII ~ = (4) -methoxyphenyl; »,. = 2.B-Dimethyl Phenyl; Z = Phenyl) The same procedure described in the Example 3, Step A, above with sodium thiocyanate (2.10 g, 25.85 mmol), the product of Step A "(crude, 25.85 mmol) and aniline (3.53 mL, 38.78 mmol) giving a white solid (1.75 g, 18%). HL-NMR (CDCla) 6 7.80-7.84 (m, 3H), 7.42 (t, 2H, 3 - 7.9 Hz), 7.18-7.28 (m, 2H), 7 , 02 (d, 2H, 3 - 7.7 Hz), 6.67 (s, $ H), 3.71 (s, 3H), 2.29 (s, 6H).

N-4-methoxy-phenyl) -2,6-dimethyl-Nl-C (2-l-ethyl-DIDERIDIN-1-yl) -phenylimino-methyl-benzamidine Step C To a solution of the product from Step A above (0.50 g, 1.28 mmol) in dimethylformamide (6 rnl) was added 2-rnethylpiperidine (0.33 g, 2.82 mmol) and l- (3-dimethylaminopropyl) -3-ethylcarbodiirnide, chlorhidate (EDCI) ) (0.27 g, 1.41 nm). The resulting mixture was stirred at room temperature for 16 hours (overnight). The reaction was concentrated in vacuo and the residue was partitioned between ethyl acetate and saturated sodium bicarbonate. The separated organic layer was dried (potassium carbonate), filtered and ethanolic hydrogen chloride was added. After concentration, the residue was purified by flash chromatography on silica gel (gradient of 100% methylene chloride to 15% methanol-rnetylene chloride) to give the title compound (0.475 g, 76%), hydrochloride salt As a solid white color. P.f. 190-192 ° C (dec); H-NMR (CDCla) d 7.52 (d, 2H, 3 = 7.6 Hz), 7.27 (t, 2H, 3 = 7.3 Hz), 7.16 (t, 1H, 3 = 7.4 Hz), 7.03 (t, 1H , 3 = 7.6 Hz), 6.83 (d, 1H, 3 = 7.1 Hz), 7.76 (d, 1H, 3 = 7.5 Hz), 6.68 (d, 2H, 3 = 9.0 Hz), 6.51 (d, 2H , 3 -9.0 Hz), 4.90 (sa, 1H), 4.32 (day, 1H, 3 = 13.6 Hz), 1.62-1.95 (m, 5H), 1.53 (d, 3H, 3 - 7.0 Hz), 1.30-1.41 (m, 2H); CIMS Ca «, Ha * N 0: 455 C (M + 1) *, 1009].

EXAMPLE 6 Scheme (3-Phenylimino-3-C2-methyl] -DÍPeridin-l-il-l-o-tolylDroPÍl) - (4-fluoro-phenyl) -amine Step fl Intermediate Product of FormXI (R- = 2-methyl phenyl: Z = phenyl) A solution of lithium bis (trimethylsilyl) amide (1 M in tetrahydrofuran, 22. 36 ml, 22.36 mmol) was added to a solution of 1-methyl acetophenone (3.0 g, 22.36 mmol) in tetrahydrofuran. (220 ml) at -78 ° C. After 15 minutes, phenyl isocyanide (2.67 ml, 22.36 mmol) was added and the resulting mixture was kept at -78 ° C for 9.5 hours and then at room temperature overnight. IN hydrochloric acid was added to the reaction and the mixture was extracted with methylene chloride. The separated organic layer was dried (potassium carbonate), filtered and concentrated. The residue was purified by flash chromatography (5% ethyl acetate-hexane) giving a strong yellow solid (4.14 g, 69%). H-NMR (CDCla (2: 1 tautomer mixture) d 14.79 (s, 1H), 10.87 (ea, 0.5 H), 8.21 (s, 1H), 7.92 (d, 0.5H, 3 - 8.1 Hz), 7.80 (d, 1H, 3 = 7.7 Hz), 7.16-7.49 (m, 12H), 5.80 (s, 1H), 4.56 (S, 1H), 2.57 (s, 1.5 H), 2.44 (s, 3H).

Step B Intermediate product of formX IR = 4-Fluorophenyl: R- = 2-methyl phenyl: Z = phenyl) A mixture of the product from Step A above (3.0 g, 11. 14 mmol), 4-fluoroanyl a (1.16 ml, 12.25 mmol) and 4-fluoroaniline hydrochloride (0.164 g, 1.11 mmol) in benzene (100 ml), was heated to reflux to remove water (Dßan-Stark trap). after 18 hours, additional 4-fluoroaniline (0.264 ml, 2.79 mmol) and 4-fluoroaniline hydrochloride (0.164 g, 1.11 mmol) were added. The reflux was maintained for another 30 hours (total reaction time 48 hours). The mixture was concentrated and the residue was triturated in diethyl ether to give a yellow solid. The solid was redissolved in methylene chloride and the organic layer was washed with brine, dried (potassium carbonate), filtered and concentrated to give a yellow solid (1.93 g, 48%) H-NMR (CDCla) or 13.65 (s, 1H), 7.97 (s, 1H), 7.15-7.40 (m, 8H), 7.07 (d, 1H, 3 = 7.3 Hz), 6.65-6.82 (m, 4H), 5.43 (S, 1H), 2.11 (s) , 3H).

Step C Intermediate Product of Formula IX (, = 4-luo-phenyl: R. = 2-methyl enyl: 2 = phenyl) Trimethyloxonium tetrafluoroborate (0.673 g, 455 mmol) was added to a solution of the product from step B above (1.50 g, 4.14 mmol) in methylene chloride (50 nl) at 0 ° C. After 15 minutes, the ice bath was removed and the reaction was allowed to stir at room temperature for 1.25 hours. The reaction mixture was washed with saturated potassium carbonate and the separated organic phase was dried (potassium carbonate), filtered and concentrated, the residue was purified by flash chromatography (methylene chloride) to give a white foam (1.28 g, 82%). P.f. 179-181 ° C; H-NMR (CDC13) d 12.47 (s, 1H), 7.22- 7.41 (rn, 5H), 7.12-7.14 (n, 2H), 7.04 (d, 2H, 3 = 7.7 Hz), 6.71 ít, 2H, 3 - 8.7 Hz), 6.54-6.56 (m, 2H), 5.02 (s, 1H), 2.35 (s, 3H), 2.18 (e, 3H); CIMS 428 C (M + 1) *, 100].

Step D (3-Phenylimino-3-C2-methyl-1-DIDERIDIN-1-yl-1-o-tolyl-DroDenyl) -k- fluoro-phenyl) -amine The same procedure described in Example 4C with the prod? C of Example C above (0.40 g, 1.06 mrnol), 2-methylpi? Eridine (0.187 rnl, 1.59 mmol), triethylamine (0.147 ml, 1.06 mmol) and silver nitrate (0.180 g, 1. 06 mmol) in acetonitrile (20 ml) to give the title compound (0.395 g, 76%), nitrate salt, as a pale yellow solid. H-NMR (CDCla) d 10.35 (sa, 1H), 8.95 (ea, 1H), 7.33 (d, 2H, 3 = 7.5 Hz), 6.99-7.22 (m, 6H), 6.93 (d, 1H, 3 = 7.2 Hz), 6.54 (t, 2H, 3 = 8.7 Hz), 6.13 (dd, 2H, 3 = 9.0 Hz, 3 = 4. 7 Hz), 4.57-4.72 (m, 1H), 4.52 (s, 1H), 4.10-4.22 (, 1H), 3.41-3.58 (m, 1H), 1.96 (s, 3H), 1.62-1.95 ( rn, 6H), 1.44 (day, 3H, 3 = 6.3 Hz); CIMS CaeHaoF at: 428 C (M + 1) *, 100].

EXAMPLE 7 Scheme 5 N-rcy ciohexiiimino- (2-metii-piDeridin-γ-ii) -methi-N-γ-4-luo-phenyl -2.6-dimethyl-t? Enzamidine Step fl Intermediate Product of Formula XIV ÍR_. = 4-fluorophenyl: R_. = 2.B-dimethylphenyl) A pure mixture of 2,6-dimethylbenzamide, N-4-fluorophenyl (6.60 g, 25.85 mmol) and phosphorus pentachloride (5.38 mg, 25.85) was heated to 120 ° C. The obtained solution was stirred for 20 minutes. Tothanol was added and the mixture was concentrated (twice). The obtained oil was dissolved in toluene (270 ml) and cooled to 0 ° C. Ammonia (g) was bubbled into the reaction mixture for 0.5 hour. The reaction was filtered and the filtrate was concentrated. The obtained residue was purified by flash chromatography on silica gel (50% ethyl acetate gradient, hexane to 100% ethyl acetate) to give an off white solid (5.02 g, 56%). H-NMR (CDCla, rotary mix) d 6.99-7.22 (m, 5H), 6.60-6.73 (m, 2H), 4.79 (s, 2H), 2.48 (s, 3H), 2.30 (s, 3H) .

Intermediate Product of Formula XIII (X = 2-met i Ipiperidine: R "= 4-luo-phenyl: R. = 7-R-diethylphenyl? Triethylamine (1.2 ml, 8.25 mmol), dimethylaminopyridine (0.10 g, 0.825 mmol) and the product from step A (2.0 g, 8.25 mmol) were added to a solution of 2-methylpiperidine-carbamoyl chloride (prepared according to the Rost method). et al., 3. Ara. Pharm. flssoc, Afi, 290 (1957)) (1.33 g, 8.25 mmol) in methylene chloride. The resulting mixture was allowed to stir at room temperature for 4 days. The mixture was washed with saturated potassium carbonate, dried (potassium carbonate), filtered and concentrated. Purification by flash chromatography on silica gel (gradient of 10% ethyl acetate-hexane to 100% ethyl acetate) gave a white foamy solid (0.832 g, 28%). H-NMR (CDCla rotamers mix) d 7.15 (t, 1H, 3 - 7.6 Hz), 6.97 (ta, 2H, 3 = 9.8 Hz), 6.76 (t, 2H, 3 = 8.6 Hz), 6.60-6.64 ( m, 2H), 4.32-5.15 (m, 2H), 2.80-3.02 (m, 1H), 2.28 (2, 3H), 2.21 (2, 3H), 1.40-1.75 (, 6H), 1.12-1.30 (m , 3H).

Step or N-rcy clohexylimino- (2-methyl-DIDERIDIN-1-yl) -methyl-hr- (4-luo-phenyl) -2,6-dimethyl-bengamidine A pure mixture of the product from Step B (0.20 g, 0. 544 nm) and phosphorus pentachloride (0.113 g, 0.544 mmol) was heated to 125 ° C and the obtained mixture was stirred for 1 hour. Toluene was added and the mixture was concentrated (doeveces). The residue was dissolved in tetrahydrofuran (8 rnl) and cyclohexylane (0.27 g) was added.2.72 mmol). The obtained mixture was stirred at room temperature for 2 hours. The reaction was filtered and the filtrate was concentrated. The residue was purified by flash chromatography on silica gel (gradient of 100% methylene chloride to 5% methanol-methylene chloride) to give the title compound (0.084 g, 34%), hydrochloride salt, co or a solid. White. p.f. 167-168 ° C; H-NMR (CDCla, rotamer mixture) d 10.90 (sa, 1H), 7.17-7.27 (m, 2H), 6.93-7.06 (, 3H), 6.76 (t, 2H, 3 = 8.5 Hz), 4.60-4.75 (m, 1H), 4.03-4.14 (m, 1H), 3.70-3.85 (m, 1H), 3.38-3.51 (m, 1H), 2.42 (s, 3H), 2.27 (s, 3H), 1.96-2.17 (ra, 2H), 1.40-1.80 (m, 14H), 1.17-1.37 (m, 3H); EIMS CaßHa-rFN «0: 448 (M *).

EXAMPLE 8 N- (4-Fluoro-phenyl) -2-methyl-N "-C4-oxo-PIDeridin-1-yl) -phenimine-methyl-benzamidine The procedure described in Example 5 was followed, Step C "with a compound of formula VII (where Ra = 4-fluorophenyl; Ra = 2-methylphenyl; Z = phenyl) (0.40 g, 1.10 mmol), 1.4 dioxa-8-azaspiroC4,53decano (0.347 g, 2.42 mmol) and EDCI (0.232 g, 1.21 mmol) in dimethyl forrnamide (6 ml) to give the NC (1,4-dioxa-8-aza-spiroC4, 5] dec-8-yl) phenylimino-methyl] -N '- (4 - fluorophenyl) -2-methyl-benzamidine (0.388 g, 69%) with a white solid. ^ H-NMR (DMS0-dA) 6 10.58 (sa, 1H), 10.15 (sa, 1H9, 7.78-7.87 ( m, 2H), 7.11-7.48 (m, 8H9, 6.91 (d, 1H, 3 = 6.3 Hz), 6.81 (d, sH, 3 = 7.0 Hz), 3.95 (e, 4H9, 3.37 (ea, 4H), 1.79 (ea, 4H9, 1.66 (e, 3H) A solution of the above product (0.350 g, 0.688 mmol) in 90% trifluoroacetic acid / ag? A (8 rnl) was stirred at room temperature for 5.75 hour. The organic layer was dried (potassium carbonate), filtered and concentrated, the residue was converted to the dissolved hydrochloride salt, and the residue was partitioned between methylene chloride and saturated potassium carbonate. in diethyl ether and bubbling hydrogen chloride (g). The precipitate obtained was collected and dried to give the title compound (0.262 g, 82%), hydrochloride salt, as an off-white solid. p.f. 234-235 ° C; H-NMR (DNSI-d *) d 10.63 (s, 1H), . 22 (s, 1H9, 7.79-7.88 (m, 2H), 7.45 (t, 1H, 3 - 7.4 Hz), 7. 13-7.39 (m, 7H), 6.93 (d, 1H, 3 = 7.4 Hz), 6.83 (d, 2H, 3 = 7. 9 Hz), 3.90-4.12 (m, 4H), 2.65 (t, 4H, 3 = 5.8 Hz), 1.63 (s, 3H); CIMS CaßHs, »FN ^ O; 429 C (M + 1) *, 100].

EXAMPLE 9 N- (4- f luoro-phenyl) -N'-IT (4-hydroxy-DIDERi din-l-l) -phenol and my non-methyl-2B-dimethyl-benzamidine Sodium hydroxide (0.006 g, 0.152 mmol) was added to a solution of the product of Example 8, free base, (0.067 g, 0.152 nmol) in ethanol (6 mL) and the mixture was stirred at room temperature for 2 hours. Saturated ammonium chloride was added and the mixture was extracted with methylene chloride (twice). The organic layer was dried (potassium carbonate), filtered and concentrated, the residue was dissolved in dioxane and hydrogen chloride (g) was bubbled. After removing the volatile components, the obtained salt was purified by flash chromatography on silica gel to give the title compound (0.033 g, 45%), hydrochloride salt, as an off-white solid. p.f. 163-165 ° C; XH-NMR ΔCDCla, mixture of rotammers) d 7.48 (d, 2H, 3 = 7.2 Hz), 7.29-7.34 (m, 3H), 7.06 (t, 1H, 3 -7.6 Hz), 6.82 (d, 2H, 3 = 7.6 Hz), 6.62-6.79 (rn, 4H), 4.109-4.36 (rn, 3H), 3.73-3.98 (m, 2H), 1.91-2.22 (, 6H), 1.60-1.81 (m, 4H); CIMS C ^ H ^ F ^ O: 445 C (M + 1) *, 100].

EXAMPLE 10 N- (4-Hydroxy-phenyl) -2,6-dimethyl-N, -C (2-methyl-PIDDEIDIN-1-iD-Phenylimino-methyl-benzamidine A solution of the product from Example 5, Step C '(0.04 g, 0.081 mmol) in aqueous hydrobromic acid (3 rnl) was heated at 110 ° C for 4 hours. The cooled reaction mixture was made alkaline by the addition of saturated sodium bicarbonate. The resulting mixture was extracted with methylene chloride and the separated organic layer was dried (potassium carbonate), filtered and concentrated. Ethanolic hydrogen chloride was added to the residue and after stirring for 15 minutes, the volatile components were removed at re-induced pressure. The salt obtained was triturated in diethyl ether to give the title compound (0.034 g, 87%). chlorhidate salt, co or a pale yellow solid. p.f. 216-218 ° C; H-NMR (DMSO-d *, mixture of rotators) d 10.60 (s, 1H), 9.53 (s, 1H9, 7.51 (d, 2H, 3 = 8.5 Hz), 7.36-7.45 (m, 1H), 7.21- 7.30 (rn, 2H, 6.95-7.12 (rn, 3H), 6.87 (d, 2H, 3 = 8.7 Hz), 6.70 (d, 2H, 3 = 7.5 Hz), 4.41-4-53 (rn, 1H), 3.88-4.01 (m, 1H9, 3.13-3.21 (rn, 1H), 1.95 (s, 3H9, 1.76 (s, 3H), 1.40-1.73 (m, 6H), 1.19-1.28 (m, 3H); CIMS 441 [(M + l) *; 100].

EXAMPLE 11 Scheme 5 N- (4-Fluoro-phenyl) - (2-methyl-N '-C (1-methyl-cyclohexy-1) -phenyliminop-p-ethyl-3-t> enza_nidinfl Step fl Intermediate Product of Formula XIV (R- = 4- fluorophenyl: R = 2-meti lfeni lo) A pure mixture of 2-methylbenzamide, N-4-fluorophenyl (4.0 g, 17.47 mmol) and phosphorus pentachloride (3.64 g, 17.47 mmol) was heated at 120 ° C for 30 minutes. Totlyne was added and the mixture was concentrated (twice). The oil obtained was dissolved in ethyl ether (50 ml) and cooled to 0 ° C. Ammonia (g) was bubbled into the reaction mixture for 20 minutes. The reaction was filtered and the filtrate was concentrated, the residue was purified by flash chromatography on silica gel (gradient of 100% chloroform to 5% methanol-chloroform) giving a white solid (1.31 g, 33%) . H-NMR (CDCla) d 7.45-7.47 (m, 1H), 7.22-7.25 (rn, 2H), 7.00-7.09 (m, 2H), 6.91-6.98 (m, 2H), 6.74-6.68 (m, 1H), 4.71-4.74 (sa, 2H), 2.53 (sa, 3H9.

Step B N- (-Fluoro-phenyl 1) - (2-methyl-N '-C (1-methyl-cyclohex r 1) - phenyiroino-ethyl-J-frenzamidine A pure mixture of 1-methyl-cyclohexylcarboxamide, N-phenyl (0.22 g, 1.0 mmol) and phosphorus pentachloride (0.21 g, 1.0 nmol) was heated at 120 ° C for 40 minutes. Then toluene was added and the mixture was concentrated (twice). The residue was dissolved in tetrahydrofuran (10 mL) and the product from Step A (0.46 g, 2 mmol) was added. The reaction was stirred at room temperature for 18 hours. The mixture was then filtered and the filtrate was concentrated. Purification by flash chromatography (chloroform) gave the title compound (0.22 g, 52%) as a white solid. P.f. 210-211 ° C; H-NMR (CDCla) d 7.26 (t, 2H, 3 = 8 Hz), 6.88-7.14 (m, 7H), 6.70 (t, 2H, 3 = 8 Hz9, 6.43-6.46 (rn, 2H), 2, 02-2.14 (m, 1H), 1.44-1.65 (m, 12H), 1.33 (s, H); EIMS CaßHaoFNa: 427 (M *).

TABLE 1 co r co in tp co co-si CQ 33 co THE uo to uo UO uo UD-yes 03 uo LEYEM3A a T-butanol was used in place of 1,4-dioxane b Acetonitrile was used instead of 1,4-diaxapo c Tetrahydrofuran (HF) was used instead of dipethylformamide (EMF) od A mixture of TOF-EMF was used 1: 1 instead of EMF oe A 2.5: 1 THF-EMF fish was used instead of EMF f Hydrochloride salt 3 Nitrate salt »El = electron shock (M >); Cl = chemical ionization W + l); Effl- bcpoardeo of fast atoms (M * + 1) * The yields given for the last step of the described Ejepplo. Unless otherwise indicated, all the compounds are isolated as hydrochloride salts. 3 [a] 2sD = -179.3 ° (c = 1.0, MeCH) k [a] 2S0 = +130, 1 ° (c = 1, 0, MeCH)

Claims (22)

1. 0), gone two *), beef; alkylamino (Cx-C *), dialkylamino (C? -C < s) and trifluorometide i; Ra is phenyl optionally substituted with one to three substituents, independently selected from the group consisting of alkyl (C? -C?), Halogen, hydroxy, (C? -C?) Alkoxy, amino, alkylamino (C? -C?), Dialkylamino ino (C-CA), -CF, -CN, -COR *, NHCOR * and tri fluorornetox i; Ra is optionally substituted phenyl with one to three substituents, independently selected from the group consisting of alkyl (C? -C?), Halogen, hydroxy, (C? -C?) Alkoxy, amino, alkylamino (C? -CA), dialkylamino (C? -C?), CFa and tri fluoromethoxy; RA and Ra are independently alkyl (C? -C?) Or R * and Ra together form with the nitrogen atom to which they are attached, a saturated heterocyclic ring of five to nine elements, in which one of the atoms of the ring can optionally be replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, where said saturated heterocyclic ring of five to nine elements can optionally be optionally substituted with one to three substituents, independently selected from the group consisting of -0R *, alkyl (Cx-C, oxo and a ketal of formula -0- (CHa) -0-; with the proviso that said substituted heterocycles are not substituted with hydroxy or a ketal adjacent to a heteroatom; R * is hydrogen or alkyl (C? -C "&), and R7 * and R? are independently alkyl (C? -C? 0) or R? and R? together form the nitrogen atom to which a heterocyclic ring is attached saturated with five to seven elements, in which one of the ring atoms can optionally be replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, where said saturated heterocyclic ring of five to seven elements can be optionally substituted with one to three substituents, independently selected from the group formed by -OR "*, alkyl (C? -C), oxo and a ketal of formula -0- (CHβ) p-0-; with the proviso that said substituted heterocycles are not substituted with hydroxy or a ketal at position two; and the pharmaceutically acceptable salts thereof.
2. 2. A compound according to claim 1, wherein Z is pyridyl or phenyl, optionally substituted with one to three substituents, independently selected from the group consisting of alkyl (C -C?), Halogen, hydroxy, alkoxy (Cx) -C ^), amino, alkylamino (Cx-C *), dialkylamino (C -C?) And tri-1-eoro-ethoxy.
3. 3. A compound according to claim 2, wherein X is NR * Ra and RA and Ra together form with the nitrogen atom to which they are attached? N saturated heterocyclic ring of optionally substituted five to nine elements, selected from piperidine, pyrrolidine, thiomorpholine, hexamethyleneimine, morpholine, thiazolidine and 1,2-tetrahydrooxazine.
4. 4. A compound according to claim 3, wherein X is an optionally substituted heterocycle selected from the group consisting of piperidine and 1,2-tetrahydoxazi a.
5. 5. A compound according to claim 3, wherein phenyl is optionally substituted with halogen, hydroxy methoxy.
6. 6. A compound according to claim 4, wherein Rs is phenyl optionally substituted with halogen, hydroxy or methoxy.
7. 7. A compound according to claim 6, wherein R a is phenyl substituted at the 4-position of the phenyl ring with fluoro or methoxy.
8. 8. A compound according to claim 3, wherein Ra is phenyl substituted with two substituents independently selected from alkyl (C -C?), Halogen, hydroxy, (C? -C?) Alkoxy, amino, alkylamino (C? - C?), Dialkylamino (C? -C?) And tri-luoroalkoxy.
9. 9. A compound according to claim 4, wherein Ra is phenyl substituted with two substituents independently selected from alkyl (Cx-C *), halogen, hydroxy, (C? -C?) Alkoxy, amino, alkylamino (C? -C?), Dialkylamino (Cx-C *) and trifluoroalkoxy.
10. 10. A compound according to claim 6, wherein Ra is phenyl substituted with two substituents independently selected from alkyl (C -C *), halogen, hydroxy, (C? -C) alkoxy, amino, alkylamino (C? -C?), dialk? yla ino (Cx-) C *) and trifluoroalkoxy.
11. 11. A compound according to claim 4, wherein said piperidine is substituted at the doe position with alkyl (C? -C_ *).
12. 12. A compound according to claim B, wherein said piperidine is substituted at the two position with alkyl (C? -C *).
13. 13. A compound according to the claim 10, wherein said piperidine is substituted at the two position with alkyl (C? -C *).
14. 14. A compound according to the claim 11, where Ra is 2,6-dimethylphenyl.
15. 15. A compound according to the claim 12, where Ra is 2,6-dimethylphenyl.
16. 16. A compound according to the claim 13, where Ra is 2,6-dimethylphenyl.
17. 17. A pharmaceutical composition for the treatment or prevention of a disease or disorder, treatment or prevention of which can be performed or facilitated by reinforcement of cholinergic neurotransmission in a mammal, comprising an amount effective for binding to a muscarinic receptor of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
18. 18. The use of an effective amount for binding to a muscarinic receptor of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, in the preparation of compositions for the treatment or prevention of a disease or disorder. , treatment or prevention which can be performed or facilitated by reinforcement of cholinergic ne rot rotrans in a mammal.
19. 19. A pharmaceutical composition for the treatment or prevention of a disease or disorder, treatment or prevention of which can be performed or facilitated by reinforcement of cholinergic neurotransmission in a mammal, comprising the administration to said mammal of an amount of? A compound according to claim 1 or a pharmaceutically acceptable salt thereof which is effective for the treatment or prevention of said disorder.
20. 20. The use of an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, in the preparation of compositions for the treatment or prevention of a disease or disorder, treatment or prevention of which it can be perform or facilitate by reinforcement of cholinergic neurotransrniation in a mammal.
21. 21. The use of a compound according to claim 1, in the preparation of compositions for the treatment, prevention or diagnosis of a disease or disorder selected from the group consisting of psychotic disorders, pain, sleep disorders, depression, fllzheimer's disease, tardive dyskinesia, Pick's disease, Huntington's chorea, Friedrich's ataxia, Gilles de la Tourette's disease, Down's syndrome, attention deficit disorder, multi-hyphatic dementia and age-related cognitive decline (flRCD) in a mammal.
22. 22. A pharmaceutical composition for the treatment, prevention or diagnosis of a disease or disorder selected from the group consisting of psychotic disorders, pain, sleep disturbances, depression, rheumatism, dyskinesia, Pick's disease, chorea, Huntington, Friedrich's ataxia, Gilles de la Tourette's disease, Down syndrome, attention deficit disorder, multi-hyphatic dementia and age-related cognitive decline (GRCD) in a mammal, comprising a quantity of a compound according to the claim 1 effective in the treatment, prevention or diagnosis of said disorder and a pharmaceutically acceptable carrier. RFSUMEN PE LQ INVENTION This invention relates to a new class of partial or total muscarinic receptor agonists, to intermediates for their preparation and to pharmaceutical compositions and method of use for the treatment or prevention of diseases, treatment or prevention of which is mediated by the agonist action on the muscarinic receptor. PF / lss * cgt * ycl P97 / 343